Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchPPIsPPIs (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
Loading...
Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Supplementary Data — PPIs for COVID-19: real-time meta analysis of 38 studies

@CovidAnalysis, October 2024, Version 25V25
Post
Share
PDF
Studies
Feedback
https://c19early.org/ppimeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Zhou (PSM) -165% 2.65 [1.75-4.00] severe case 151/524 173/2,620 Improvement, RR [CI] Treatment Control Yao -600% 7.00 [4.57-10.7] severe case 694 (n) 2,330 (n) Yao -2501% 26.01 [14.11-48.0] severe case 82 (n) 2,330 (n) Yao -95% 1.95 [1.09-3.48] severe case 537 (n) 2,330 (n) Liwang -204% 3.04 [1.22-7.60] death 216 (n) 149 (n) LD​1​ Yan -240% 3.40 [2.00-5.79] severe case 16/32 20/136 Blanc 56% 0.44 [0.23-0.82] cases 63 (n) 116 (n) Freedberg (PSM) -34% 1.34 [1.06-1.69] death/int. 8/84 332/1,536 Argenziano 1% 0.99 [0.73-1.34] ICU 38/163 198/837 Argenziano -9% 1.09 [1.03-1.15] hosp. 149/163 701/837 Vila‐Corcoles -9% 1.09 [0.80-1.50] cases 11,807 (n) 23,129 (n) Lee (PSM) -79% 1.79 [1.30-3.10] severe case 267 (n) 267 (n) Lee (PSM) -63% 1.63 [1.03-2.53] severe case 267 (n) 267 (n) Lee (PSM) 10% 0.90 [0.78-1.01] cases 13,873 (n) 13,873 (n) Luxenburger -248% 3.48 [1.29-9.39] death 12/62 5/90 Luxenburger -124% 2.24 [1.13-4.45] ARDS 17/62 11/90 Luxenburger -86% 1.86 [1.06-2.83] misc. 30/62 18/90 Almario -179% 2.79 [1.65-4.70] cases Almario -267% 3.67 [2.93-4.60] cases Almario -115% 2.15 [1.90-2.44] cases García-Menaya -228% 3.28 [1.22-9.94] death 15/54 5/59 García-Menaya -392% 4.92 [1.06-32.6] ICU 9/54 2/59 Mas Romero 26% 0.74 [0.38-1.45] death 11/82 21/116 Mas Romero -8% 1.08 [0.89-1.31] symp. case 58/82 76/116 Fan (PSM) -17% 1.17 [0.65-2.90] death n/a n/a Fan (PSM) 4% 0.96 [0.59-1.55] death n/a n/a Fan (PSM) 14% 0.86 [0.52-1.45] death n/a n/a Fan (PSM) 20% 0.80 [0.58-1.11] death n/a n/a Fan (PSM) -22% 1.22 [0.93-1.60] cases n/a n/a Fan (PSM) -8% 1.08 [0.89-1.31] cases n/a n/a McKeigue -44% 1.44 [1.31-1.58] severe case case control Zhang (PSM) -11% 1.11 [0.92-1.33] hosp. time 29 (n) 29 (n) Zhang 6% 0.94 [0.57-1.54] no disch. 35 (n) 119 (n) Zhang 37% 0.63 [0.40-1.01] viral+ 35 (n) 119 (n) Elmunzer 13% 0.87 [0.66-1.14] death 417 (n) 1,429 (n) Elmunzer -2% 1.02 [0.73-1.43] ventilation 417 (n) 1,429 (n) Morán Blanco 31% 0.69 [0.36-1.33] symp. case 12/48 13/36 Cheung 25% 0.75 [0.07-6.00] severe case 4 (n) 948 (n) Liu -127% 2.27 [1.64-3.13] death 68/227 53/459 Jimenez -124% 2.24 [1.80-2.80] death 1,357 (all patients) Jimenez -118% 2.18 [1.64-2.91] death 1,357 (all patients) Jimenez -133% 2.33 [1.66-3.27] death 1,357 (all patients) Israelsen (PSM) 5% 0.95 [0.74-1.22] death 166/3,955 189/3,955 Israelsen (PSM) 12% 0.88 [0.72-1.08] death 166/3,955 189/3,955 Israelsen (PSM) -8% 1.08 [0.71-1.64] ventilation 55/3,955 55/3,955 Israelsen (PSM) 0% 1.00 [0.69-1.45] ventilation 55/3,955 55/3,955 Israelsen (PSM) -5% 1.05 [0.75-1.46] ICU 92/3,955 95/3,955 Israelsen (PSM) 3% 0.97 [0.73-1.29] ICU 92/3,955 95/3,955 Israelsen (PSM) -22% 1.22 [1.06-1.40] hosp. 734/3,955 650/3,955 Israelsen (PSM) -13% 1.13 [1.03-1.24] hosp. 734/3,955 650/3,955 Israelsen -8% 1.08 [1.03-1.13] cases case control Shah 3% 0.97 [0.85-1.10] death 6,262 (n) 8,696 (n) Shah -21% 1.21 [0.99-1.48] ventilation 6,262 (n) 8,696 (n) Shah -13% 1.13 [0.99-1.28] ICU 6,262 (n) 8,696 (n) Shah -5% 1.05 [0.97-1.15] hosp. 6,262 (n) 8,696 (n) Ramachandran -92% 1.92 [1.11-2.99] death 16/46 40/249 Ramachandran -80% 1.80 [1.13-2.56] progression 18/46 55/249 Shafrir (PSM) -47% 1.47 [0.77-2.80] severe case 22/655 15/655 Shafrir -16% 1.16 [0.88-1.51] severe case Shafrir (PSM) 8% 0.92 [0.85-1.00] cases 880/6,835 956/6,835 Shafrir 5% 0.95 [0.90-1.01] cases population-based cohort Wu (PSW) -197% 2.97 [1.63-5.42] death 1,046 (n) 3,588 (n) Wu (PSM) -10% 1.10 [1.01-1.19] viral+ 1,046 (n) 3,588 (n) Shupp 19% 0.81 [0.54-1.22] death 448 (n) 2,048 (n) Shupp -10% 1.10 [0.83-1.45] hosp. 448 (n) 2,048 (n) Kodvanj 7% 0.93 [0.85-1.02] death Kodvanj -4% 1.04 [0.97-1.13] hosp. Kim (PSM) -28% 1.28 [0.48-3.37] death 9/437 7/437 Kim (PSM) -75% 1.75 [0.51-5.79] ventilation 7/437 4/437 Kim (PSM) -150% 2.50 [0.79-7.65] ICU 10/437 4/437 Kim (PSM) -21% 1.21 [0.61-2.39] progression 17/437 14/437 Kim (PSM) 37% 0.63 [0.53-0.75] cases 226/9,913 341/9,913 Shokri -81% 1.81 [1.01-3.25] severe case 121 (n) 549 (n) Shokri -138% 2.38 [1.41-3.34] severe case 40 (n) 549 (n) Shokri -30% 1.30 [0.64-1.96] severe case 81 (n) 549 (n) Elkanzi -17% 1.17 [0.76-1.81] death 36/159 29/150 Elkanzi -25% 1.25 [1.00-1.56] ICU 90/159 68/150 Elkanzi -126% 2.26 [0.82-6.27] progression 12/159 5/150 Elkanzi -33% 1.33 [1.09-1.62] progression 104/159 74/150 Elkanzi 19% 0.81 [0.60-1.10] hosp. time 159 (n) 150 (n) Patil -48% 1.48 [1.32-1.66] death 4,566 (n) 15,349 (n) Patil -119% 2.19 [1.91-2.50] ARDS 4,566 (n) 15,349 (n) Patil -88% 1.88 [1.73-2.05] misc. 4,566 (n) 15,349 (n) Patil -73% 1.73 [1.48-2.02] oxygen 4,566 (n) 15,349 (n) Gramont (PSW) -59% 1.59 [1.18-2.14] severe case 424 (n) 410 (n) Cheung -49% 1.49 [1.13-1.98] death population-based cohort Cheung -54% 1.54 [1.21-1.97] death population-based cohort Cheung 21% 0.79 [0.23-2.81] death population-based cohort Cheung -36% 1.36 [0.79-2.35] severe case population-based cohort Cheung -57% 1.57 [1.24-1.98] severe case population-based cohort Cheung 21% 0.79 [0.27-2.28] severe case population-based cohort Cheung -20% 1.20 [1.09-1.32] hosp. population-based cohort Cheung -20% 1.20 [1.08-1.32] hosp. population-based cohort Cheung -21% 1.21 [0.92-1.60] hosp. population-based cohort Cheung -9% 1.09 [1.05-1.13] cases population-based cohort Cheung -7% 1.07 [1.05-1.10] cases population-based cohort Cheung -11% 1.11 [1.07-1.15] cases population-based cohort Hirsch 15% 0.85 [0.64-1.13] hosp. 116,209 (all patients) Hirsch 15% 0.85 [0.76-0.94] cases 116,209 (all patients) Al-Momani -100% 2.00 [0.46-8.71] death 3/69 4/184 Al-Momani -48% 1.48 [0.51-4.27] ventilation 5/69 9/184 Al-Momani -25% 1.25 [0.57-2.77] ICU 8/69 17/184 Zeng -46% 1.46 [1.05-2.03] death population-based cohort Zeng -33% 1.33 [1.09-1.61] severe case population-based cohort Zeng -8% 1.08 [0.99-1.17] cases population-based cohort Pinto -57% 1.57 [0.90-2.74] hosp. 15/104 38/414 PPI COVID-19 outcomes c19early.org October 2024 ​1​ LD: comparison with low dose treatment Favors PPI Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0